Research article
An investigation of the effects of lipid-lowering medications: genome-wide linkage analysis of lipids in the HyperGEN study
-
* Corresponding author: Jun Wu jwu@wustl.edu
1 Division of Statistical Genomics, Washington University School of Medicine, Campus Box 8506, 4444 Forest Park Boulevard, Saint Louis, MO63108, USA
2 Department of Psychiatry, University of Utah, Salt Lake City, UT, USA
3 Cardiovascular Genetics, University of Utah, Salt Lake City, UT, USA
4 Department of Laboratory Medicine & Pathology, University of Minnesota, Minneapolis, MN, USA
5 University of Alabama at Birmingham, Birmingham, AL, USA
6 Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA
7 Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
8 Section of Preventive Medicine and Epidemiology, Boston University School of Medicine, Boston, MA, USA
9 Division of Biostatistics, Washington University School of Medicine, Saint Louis, MO, USA
BMC Genetics 2007, 8:60 doi:10.1186/1471-2156-8-60
Published: 10 September 2007Additional files
Additional file 1:
Appendix A and Appendix B. Appendix A includes Table A1 and A2 showing the detailed results from individual clinical trials for HMG-CoA Inhibitors and Fibric Acid Derivatives as mono-drug therapy, along with Figure A1-A4 for multipoint genome scan results of lipids in HyperGEN based on SEGPATH software. Appendix A may also be found on the following website: http://www.biostat.wustl.edu/hypergen/results.html webcite. Appendix B lists the citations for all clinical trials summarized in Table A1 and A2.
Format: PDF Size: 566KB Download file
This file can be viewed with: Adobe Acrobat Reader
